Needham reiterated coverage on Trevi Therapeutics with a new price target
$TRVI
Biotechnology: Pharmaceutical Preparations
Health Care
Needham reiterated coverage of Trevi Therapeutics with a rating of Buy and set a new price target of $25.00 from $8.00 previously